开发生物标志物与风险分层方法:2024年北美国际肾癌研讨会智库的共识声明
该共识采用改良德尔菲法,由多学科专家组经3轮(含线下会议)对20条初始声明进行评审与投票,以Likert评分中位数≥8定义为达成共识,最终通过19条共识声明。声明涵盖生物标志物优先级(倾向预后生物标志物)、亚组与预测分析的严谨方法、多机构前瞻性登记库建设、将生物标志物纳入试验设计以及改善数据/生物样本获取,并确定AI图像分析、ctDNA等高优先级生物标志物类型用于未来研究。
要点
- 共识支持优先开发预后生物标志物,并强调亚组与预测分析需采用严谨方法。
- 建议建设多机构前瞻性登记库,并将生物标志物整合到临床试验设计中。
- AI图像分析与ctDNA被列为未来研究的高优先级生物标志物类型。
核心结论
- 该共识为肾癌生物标志物与风险模型开发提供框架,强调严谨方法、协作基础设施、前瞻性数据收集及聚焦临床可转化生物标志物。
研究设计与样本
- 改良德尔菲法共识,多学科专家组经3轮(含线下会议)对20条初始声明评审投票,共识预先定义为Likert评分中位数≥8,最终19条声明获通过。
诊断标准与关键数值
- 共识达成标准为Likert评分中位数≥8。
- 初步20条声明经3轮评审后,19条最终共识声明获通过。
临床应用与阅片要点
- 共识推荐优先发展预后生物标志物,并采用严谨方法开展亚组与预测分析。
- 共识推荐建设多机构前瞻性登记库,并将生物标志物纳入试验设计。
- 共识推荐改善数据与生物样本的可及性。
- 专家组将AI图像分析与ctDNA列为未来研究的高优先级生物标志物类型。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Accurate prognostication and personalized treatment selection remain major challenges in kidney cancer. This consensus initiative aimed to provide actionable expert guidance on the development and clinical integration of prognostic and predictive biomarkers and risk stratification tools to improve patient care and guide future research. A modified Delphi method was employed to develop consensus statements among a multidisciplinary panel of experts in urologic oncology, medical oncology, radiation oncology, pathology, molecular biology, radiology, outcomes research, biostatistics, industry, and patient advocacy. Over 3 rounds, including an in-person meeting 20 initial statements were evaluated, refined, and voted on. Consensus was defined a priori as a median Likert score ≥8. Nineteen final consensus statements were endorsed. These span key domains including biomarker prioritization (favoring prognostic biomarkers), rigorous methodology for subgroup and predictive analyses, the development of multi-institutional prospective registries, incorporation of biomarkers in trial design, and improvements in data/biospecimen access. The panel also identified high-priority biomarker types (e.g., AI-based image analysis, ctDNA) for future research. This is the first consensus statement specifically focused on biomarker and risk model development for kidney cancer using a structured Delphi process. The recommendations emphasize the need for rigorous methodology, collaborative infrastructure, prospective data collection, and focus on clinically translatable biomarkers. The resulting framework is intended to guide researchers, cooperative groups, and stakeholders in advancing personalized care for patients with kidney cancer.
引用
- Shapiro DD, Abel EJ, Albiges L, et al. Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank. Urol Oncol. 2025. PMID: 40820078. doi:10.1016/j.urolonc.2025.07.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。